(MENAFN- EIN Presswire) Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals. LAS VEGAS ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

Clostridioides difficile (C. diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC). It can worsen symptoms and cause complications. It can also trigger a ...

Although more evidence is needed, probiotics may help your immune system by creating and maintaining a healthy gut microbiome ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Specifically, Vowst is used in adults to help prevent Clostridioides difficile (C. diff) infections that have already been treated from coming back. Note that this drug isn’t used to treat C.

Pfizer's vaccine for Clostridium difficile (C. US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

diff infection (CDI) instead of aiming to reduce the risk and prevention of disease. Pfizer estimates ~500k infections annually in the U.S., and no vaccine options currently available ...

Clostridium difficile infection (CDI) is considered to be the main cause of bacterial infectious diarrhea in nosocomial settings. Since the beginning of the new century a continuous rise in the ...